A biotech thought it was investing in a smallpox treatment that would only be needed in a bioterrorism attack. Now it is one of the few available monkeypox treatments.
Tpoxx capsules processed this week at Packaging Coordinators Inc. in Philadelphia.Updated Aug. 25, 2022 12:03 pm ET
In the aftermath of 9/11, SIGA Technologies Inc. started work on a drug it hoped would never be used. Now, Tpoxx is playing a surprising role as one of the few available treatments thought to be effective against monkeypox. SIGA’s employees spent nearly two decades developing Tpoxx to treat smallpox in case of a bioterrorism attack.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: